Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
11. |
ECCT/14/11/01 | ZEBOV Trial A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Volunteers in Kilifi, Kenya. |
Principal Investigator(s) 1. Philip Bejon 2. Patricia Njuguna Site(s) in Kenya KEMRI Wellcome Trust Research Programme |
08-12-2014 |
View |
12. |
ECCT/14/11/02 | A5297 An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium falciparum Subclinical Parasitemia in HIV-infected Adults with CD4+ Counts >200 and < 500 cells/mm3 |
Principal Investigator(s) 1. VICTOR AKELO Site(s) in Kenya KEMRI/CDC CLINICAL RESEARCH CENTRE |
02-02-2015 |
View |
13. |
ECCT/15/04/02 | Plasma concentration profiles after oral administration of oleylphosphocholine tablet formulation: safety, tolerability and pharmacokinetics of 100 mg single dose in healthy male volunteers. |
Principal Investigator(s) 1. Ravasco Rashid Juma Site(s) in Kenya KEMRI |
15-06-2015 |
View |
14. |
ECCT/14/09/03 | Breast Feeding Study An open-label, short-duration, repeat-dose study of breast milk excretion and infant absorption of daily oral Tenofovir Disoproxil Fumarate/Emtricitabine when used by HIV-1 uninfected lactating women |
Principal Investigator(s) 1. Jared Murray Baeten 2. Nelly Rwamba Mugo Site(s) in Kenya Partners in Prevention, Thika Site |
19-08-2015 |
View |
15. |
ECCT/15/11/04 | VAC040 A Phase 1/2, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Tolerability, and Immunogenicity of Stretococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide (PATH-wSP) in Healthy Kenya Young Adults (18 - 40years) and Toddlers (12 - 19months) |
Principal Investigator(s) 1. John Anthony Gerard Scott Site(s) in Kenya KEMRI-Wellcome Trust Research Program |
09-02-2016 |
View |
16. |
ECCT/15/10/01 | VRC01 Monoclonal HIV Antibodies Study Safety and Virologic Effect Of A Human Monoclonal Antibody, VRC-HIVmAb060-00-Ab (VRCOl), With Broad HIV-1 Neutralizing Activity, Administered Intravenously to Adults During Early Acute HIV Infection. |
Principal Investigator(s) 1. Josphat K Kosgei Site(s) in Kenya KEMRI Walter Reed Project Kericho |
20-03-2016 |
View |
17. |
ECCT/16/02/01 | ASSESSING THE ACCURACY, USABILITY AND ACCEPTABILITY OF CHILDREN’S AUTOMATED RESPIRATORY MONITOR AT SELECTED CLINICS IN TURKANA COUNTY, KENYA ‘ ASSESSING THE ACCURACY, USABILITY AND ACCEPTABILITY OF CHILDREN’S AUTOMATED RESPIRATORY MONITOR AT SELECTED CLINICS IN TURKANA COUNTY, KENYA ‘ |
Principal Investigator(s) 1. ISAIAH MWANGI Site(s) in Kenya 1. lodwar hospital (Turkana county) |
21-03-2016 |
View |
18. |
ECCT/16/06/01 | P1115 Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study |
Principal Investigator(s) 1. Fredrick Sawe Site(s) in Kenya KEMRI WALTER REED PROJECT KERICHO |
25-07-2016 |
View |
19. |
ECCT/16/08/03 | IMPAACT 2001 A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection |
Principal Investigator(s) 1. Deborah Chepngeno Langat Site(s) in Kenya Kenya Medical Research Institute Walter Reed project |
27-10-2016 |
View |
20. |
ECCT/16/11/02 | IMPAACT P1093 Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and AdolescentsPhase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents |
Principal Investigator(s) 1. Lucy Koech Site(s) in Kenya KENYA MEDICAL RESEARCH INSTITUTE/WALTER REED PROJECT HIV PROGRAME |
28-03-2017 |
View |